SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced that enrollment has commenced in a phase 2 clinical trial designed to evaluate the efficacy and safety of FG-3019, a fully human monoclonal antibody against connective tissue growth factor (CTGF), in patients with type 2 diabetes and advanced kidney disease.
